Press releases
These press releases are intended for journalists and analysts/investors.
-
TGA approves Arexvy [Recombinant Respiratory Syncytial Virus (RSV) adjuvanted vaccine] for adults 50-59 years old at increased risk for RSV disease
The TGA has approved a new indication for AREXVY for use in adults 50-59 years of age who are at increased risk of RSV.
-
GSK brings Australian research discovery Omjjara (momelotinib) home: new treatment PBS listed for rare bone marrow cancer
Omjjara (momelotinib) is available on the Pharmaceutical Benefits Scheme (PBS) to treat the rare bone marrow cancer, myelofibrosis.
-
GSK & ViiV Healthcare Australia Gender Pay Gap Explanatory Statement - 2025
GSK Australia and Viiv Healthcare's statement on the Australian Gender Pay Gap from the 2023/2024 reporting period.
-
Aussie stars expose the painful reality of shingles this Shingles Awareness Week
Australian celebrities share shingles stories during Shingles Awareness Week, educating of the risks, symptoms, and prevention for shingles.
-
Local scientific discovery Omjarra (momelotinib) now TGA approved for Australians with rare bone marrow cancer
Omjjara (momelotinib) is TGA approved for rare bone marrow cancer, joining few Australian discoveries with both FDA and TGA approval.
-
Decades worth of groundbreaking brain disease research wins Australian scientist the 2024 GSK Award for Research Excellence
Professor Matthew Kiernan has won the prestigious 2024 GSK Award for Research Excellence for his work in neurodegenerative disease.
-
New report: Investment in adult vaccination can deliver a $1.1bn net annual return
Increasing investment in adult immunisation has the potential to deliver $1.1billion in benefits every year.
-
More Australians to have access to funded shingles vaccine
The Government expands access to Shingrix for moderate to high risk individuals aged 18 to 64, as advised by ATAGI.
-
Doctors urge parents to be vigilant with further invasive meningococcal disease infections expected early spring
Invasive meningococcal disease cases are expected to peak in winter and early spring.
-
Shelley Craft hits the road to drive health education in regional northern NSW
Australian TV personality Shelley Craft and Dr Lisa Beecham are bringing health education to local regional communities in northern NSW.
-
Australian icon Ita Buttrose champions new RSV awareness campaign
Ita Buttrose AC, OBE is partnering with GSK to launch an education campaign aimed at informing older Australians of the risks of RSV.
-
Jemperli (dostarlimab) is now listed on the PBS in combination with chemotherapy as a first line treatment for women with dMMR primary advanced or recurrent endometrial cancer.
Other than chemotherapy, Jemperli (dostarlimab) is the first PBS reimbursed treatment option for dMMR endometrial cancer.
-
New survey research exposes lack of shingles awareness among at-risk Australians
Nearly all Australians over the age of 50 carry the inactive virus that causes shingles from a previous chickenpox infection.
-
GSK & ViiV Healthcare Australia Gender Pay Gap Explanatory Statement - 2024
GSK and ViiV's 2024 explanatory statement on the gender pay gap with WGEA
-
Australia’s first RSV (respiratory syncytial virus) vaccine AREXVY approved by TGA
Australia’s first RSV (respiratory syncytial virus) vaccine AREXVY approved by TGA.
-
Researcher’s work on ‘kiss of death’ protein gets industry accolades
Professor David Komander – Head of the Ubiquitin Signalling Division at WEHI – has won the 2023 GSK Award for Research Excellence (ARE).
-
Australians at risk of shingles have access to a newly funded vaccine
GSK Australia welcomes the listing of Shingrix on the National Immunisation Program.
-
This Pain Awareness Month, leading Geriatrician calls for greater awareness of shingles
GSK Australia recently commissioned a survey which has cast a spotlight on the lack of awareness surrounding shingles.
-
Experts remind to watch out for early signs of invasive meningococcal disease as we enter peak season
Professor Robert Booy is reminding Australians to stay vigilant for the signs and symptoms of invasive meningococcal disease (IMD).
-
Nucala® (mepolizumab) is now listed on the PBS for Australians with chronic rhinosinusitis with nasal polyps
GSK Australia welcomes the PBS funding of Nucala for the treatment of severe chronic rhinosinusitis with nasal polyps.
